Ceftobiprole Medocaril Sodium

China [CN]

1. Core Uses

Approved Indications (all for intravenous administration):

Community-acquired pneumonia (CAP)

Hospital-acquired pneumonia (HAP, excluding VAP)

Acute bacterial skin and soft tissue infections (ABSSSI)

Staphylococcus aureus bacteremia (including right-sided infective endocarditis)

Mechanism: The prodrug is rapidly converted to ceftobiprole in the body by esterases, inhibiting cell wall synthesis by binding to PBPs; its unique binding to PBP2a provides anti-MRSA activity; it also covers multidrug-resistant Gram-negative bacteria, making it a first-line choice for severe infections.

2. Key Clinical Information

Dosage Form: Sterile powder for injection (500mg, 1000mg, calculated as ceftobiprole)

Dosage and Administration: Adults 500mg every 8 hours or 1000mg every 12 hours, administered by intravenous infusion over 30–60 minutes; dose reduction is required for patients with renal impairment.

Core Advantages:

Anti-MRSA: One of the few fifth-generation cephalosporins with potent activity against MRSA

Broad-spectrum coverage: Full coverage of G+ (MRSA, streptococci) and G- (Pseudomonas aeruginosa, Enterobacteriaceae) bacteria

Prodrug design: Good water solubility, convenient intravenous administration, and rapid activation in the body

Suitable for severe infections: Used for multidrug-resistant bacterial infections, reducing mortality